Lilly licenses Cipla to sell tirzepatide in India under the brand Yurpeak
The deal gives Lilly a second brand name for its tirzepatide pen in India, a change that does not alter the medicine's strengths, price or U.S. availability [1].
Eli Lilly signed an agreement with Cipla that allows the Indian drugmaker to sell Lilly's tirzepatide under a separate brand in India, the companies said on Oct. 23. Lilly will manufacture the drug and Cipla will market it under the brand name Yurpeak [1].
Yurpeak will be sold as a once-weekly pre-filled injector pen, the same format as Lilly's Mounjaro Kwikpen. It will come in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, and will be priced the same as Mounjaro [1]. The financial terms of the licensing agreement were not disclosed [1].
Lilly began selling Mounjaro in India in late March, for diabetes and obesity, in 2.5 mg and 5 mg vials. It later received approval from India's drug regulator for the Kwikpen device in June, and sales of the drug more than doubled within months of its launch [1].
Tirzepatide belongs to a class of therapies known as GLP-1 receptor agonists, which help control blood sugar and slow digestion, making people feel fuller for longer [1].
Why it matters for patients
For patients in the United States, this is a licensing and marketing arrangement in another country. Yurpeak is an India-only brand name. It is not a new molecule, a new device or a new dose: it is the same medicine, from the same manufacturer, in the same pen format and the same six strengths as the Mounjaro Kwikpen [1].
That means the deal does not, by itself, change what is stocked in U.S. pharmacies or what it costs here. Whether the agreement affects U.S. supply or pricing in any way has not been reported [1].
The practical consequence is about names. A patient who travels to India could see tirzepatide sold as Yurpeak rather than Mounjaro, with the same strengths printed on the pen [1]. Comparing prescriptions across countries means comparing brand names that differ for the same drug.
Why Lilly wants two brand names for one drug in the same market is not explained in the announcement [1]. The company has not said whether Yurpeak is intended to reach a different group of patients, a different channel of pharmacies or a different price segment than Mounjaro, beyond stating that the pricing is the same [1].
Whether Yurpeak is approved in India for both diabetes and obesity, as Mounjaro is, has not been reported [1]. Nor has the companies' reasoning about how a second brand affects competition with other weight-loss and diabetes medicines sold in India [1].
What happens next
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.